TheraVet Announces the Initiation of Coverage of Its Stock by Degroof Petercam
10 Janvier 2022 - 5:58PM
Business Wire
Regulatory News:
TheraVet (code ISIN: BE0974387194 - mnémonique: ALVET)
(Paris:ALVET) (Brussels:ALVET), a pioneering company in the
management of osteoarticular diseases in companion animals,
announces today the initiation of commissioned research coverage of
its title by Degroof Petercam, with a study entitled
"Revolutionizing the treatment of osteoarticular diseases".
The Degroof Petercam study presents a target valuation range of
€9.40 to €15.90 per share*.
Click here to access the document,
which is also available on the company's investor website:
https://www.theravet-finances.com/
* The target valuation range was established on 7 January 2022 -
and was first published on 10 January 2022. This information does
not constitute an offer to sell or subscribe or the solicitation of
an order to buy or subscribe securities in France, Europe, the
United States or any other country. Degroof Petercam has been
appointed and is being paid by TheraVet to issue this coverage. The
report is considered a marketing communication and has not been
prepared in accordance with the legal requirements of independent
investment research. Nor is it subject to any prohibition on
trading prior to the release of the investment research. The
content of the report is prepared by Degroof Petercam, without any
intervention from TheraVet.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for animals. The Company develops
targeted, safe and effective treatments to improve the quality of
life of pets suffering from osteoarticular diseases. For pet
owners, the health of their pets is a major concern and TheraVet’s
mission is to address the need for innovative and curative
treatments. TheraVet works closely with international opinion
leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris et Brussels, its head office is in
Gosselies, Belgium, and it has a subsidiary in the US.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220110005747/en/
TheraVet Sabrina Ena Chief Operating Officer
sabrina.ena@thera.vet Tel: +32 71 96 00 43
Julie Winand Chief Corporate Officer julie.winand@thera.vet
NewCap Investor Relations and Financial Communications
Théo Martin / Olivier Bricaud theravet@newcap.eu Tel: +33 1 44 71
94 94
Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu
Tel: +33 1 44 71 00 15
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
TheraVet (EU:ALVET)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024